| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FABP2 |
| Uniprot No | P12104 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-132aa |
| 氨基酸序列 | AFDSTWKVDRSENYDKFMEKMGVNIVKRKLAAHDNLKLTITQEGNKFTVKESSAFRNIEVVFELGVTFNYNLADGTELRGTWSLEGNKLIGKFKRTDNGNELNTVREIIGDELVQTYVYEGVEAKRIFKKD |
| 预测分子量 | 17.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于FABP2重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *"Expression and characterization of recombinant rat intestinal fatty acid-binding protein in Escherichia coli"*
**作者**: Luxon, B.A., & Milliano, M.T.
**摘要**: 该研究利用大肠杆菌表达系统成功制备了重组大鼠FABP2蛋白，并验证其与长链脂肪酸(如油酸)的特异性结合能力，为后续功能研究提供纯化蛋白基础。
2. **文献名称**: *"A polymorphism in the human intestinal fatty acid-binding protein alters fatty acid transport across Caco-2 cells"*
**作者**: Baier, L.J., et al.
**摘要**: 研究通过构建携带Ala54Thr突变的重组人FABP2蛋白，发现该基因多态性显著增强蛋白对脂肪酸的亲和力，可能解释其与胰岛素抵抗及代谢疾病的关联。
3. **文献名称**: *"Solution structure and backbone dynamics of human intestinal fatty acid-binding protein: Implications for ligand entry and exit"*
**作者**: Thompson, J.R., et al.
**摘要**: 利用核磁共振(NMR)技术解析重组人FABP2的三维结构，揭示其脂肪酸结合口袋的动态构象变化，提出“门户区域”调控配体结合的分子机制。
---
如需扩展，可补充2010年后应用研究(如疾病模型或药物开发相关文献)。以上内容基于经典研究整合，建议通过PubMed或Google Scholar核对原文细节。
Fatty Acid-Binding Protein 2 (FABP2), also known as intestinal FABP, is a small cytoplasmic protein predominantly expressed in the epithelial cells of the small intestine. It belongs to the FABP family, which plays a critical role in the solubilization, transport, and metabolic regulation of dietary lipids. FABP2 specifically binds long-chain fatty acids (LCFAs) with high affinity, facilitating their absorption from the intestinal lumen and subsequent intracellular trafficking to sites of metabolism or storage. Its expression is closely linked to dietary fat intake, making it a key mediator in lipid homeostasis.
Structurally, FABP2 consists of ~131 amino acids (15 kDa) and adopts a β-barrel fold with a hydrophobic ligand-binding pocket. This conformation enables reversible interactions with fatty acids, bile acids, and other lipophilic molecules. A well-studied genetic variant, Ala54Thr polymorphism in FABP2. has been associated with altered lipid metabolism, insulin resistance, and increased risk of metabolic disorders like obesity and type 2 diabetes, highlighting its physiological relevance.
Recombinant FABP2 is typically produced using prokaryotic (e.g., *E. coli*) or eukaryotic expression systems, followed by purification via affinity chromatography. Its recombinant form retains native ligand-binding properties, enabling in vitro studies on fatty acid uptake mechanisms, membrane transport dynamics, and interactions with metabolic enzymes. Researchers also utilize recombinant FABP2 as a biomarker in clinical studies to assess intestinal lipid malabsorption, inflammatory bowel diseases, or metabolic syndrome. Additionally, it serves as a tool for screening therapeutic compounds targeting lipid-related disorders or optimizing dietary interventions. Ongoing research continues to explore its role in gut-brain axis signaling and microbiota-host lipid interactions.
×
